2026 Q2 - tulosraportti
Vain PDF
46 päivää sitten
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 150 | - | - | ||
| 2 000 | - | - | ||
| 354 | - | - | ||
| 3 266 | - | - | ||
| 2 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 - tulosraportti 5.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 21.8. | ||
2026 Q1 - tulosraportti 6.5. | ||
2025 Q4 - tulosraportti 27.2. | ||
2025 Q3 - tulosraportti 5.11.2025 | ||
2025 Q2 - tulosraportti 22.8.2025 |
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
·11.9.The positive thing is that the decline so far does not seem to be linked to any new negative clinical announcement. The company's latest major announcement is still that ASPIRE is fully recruited and that topline data is expected in mid-2027.
Short selling has increased steadily, at least 0.1% per day over the past 1-2 weeks. Difficult with such low trading volume to absorb the increased supply of shares without putting downward pressure on the share price.- ·9.9. · MuokattuPharmaceutical company Vicore Pharma tops the list with a potential upside of 268%. The company develops treatments for lung diseases. Vicore has a drug candidate in a clinical study, with study data expected in 2027. In 2025, the company had a turnover of 3.8 Mkr and made a loss of 478 Mkr. Rank Company Upside to average target price in % 1 Vicore Pharma 268% 2 BioInvent International 267% 3 Verve Group Media 99% 4 Verisure 73% 5 Hansa Biopharma 69% Source: Factset
- ·4.9.Response from Vicore regarding ASPIRE and the path towards phase 3 I sent some questions to Vicore now that ASPIRE is fully recruited and the company is entering the waiting period for the results. Hans at Vicore replied: 1. Can a continued study after the futility analysis be seen as a positive sign? Response from Vicore: The futility analysis is conducted by an independent committee and Vicore will remain blinded to the results regarding treatment effect. A decision to continue the study only means that the committee has not identified reasons to discontinue the study due to a low probability of achieving the objective. 2. How much phase 3 work can be done already now? Response from Vicore: Some of the preparations can be made already before the ASPIRE results, for example CMC, clinical pharmacology, regulatory planning, market analyses, KOL dialogues and various scenarios for phase 3 design. The final decisions will, however, be based on ASPIRE data. 3. What will be most important when the ASPIRE results arrive? Response from Vicore: The primary endpoint, change in FVC over 52 weeks, will be central. At the same time, the overall picture will be important, including safety, tolerability and how the results position buloxibutid in the future treatment landscape for IPF. My own thought: I think the answers are quite clear. I would not interpret a decision to continue after the futility analysis as any confirmation of efficacy – Vicore themselves also state this clearly. However, I find it interesting that the company is already preparing several parts for a possible phase 3 study. They are thus working on the next step, while also being clear that the final decisions will be based on the ASPIRE results. Now, what truly remains is the most important thing: the FVC result after 52 weeks and the overall picture regarding efficacy, safety, and tolerability. That is where we will find out if buloxibutid truly has the potential to take the next big step. Thanks to the company for clear answers.
·2.9.In the coming days, several presentations of the company's product will be held at various conferences around the world. Funding to conduct the progressive operations in the form of studies, etc., is available. It will be interesting to see where the price settles in the future; today was a good opportunity to add to my position, which I have done. 🙏
·1.9.Danske Bank's increase of the target price to 25kr (20) might remind the market about the potential in this..
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 215 589 | 215 589 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 215 589 | 215 589 | 0 | 0 |
2026 Q2 - tulosraportti
Vain PDF
46 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·11.9.The positive thing is that the decline so far does not seem to be linked to any new negative clinical announcement. The company's latest major announcement is still that ASPIRE is fully recruited and that topline data is expected in mid-2027.Short selling has increased steadily, at least 0.1% per day over the past 1-2 weeks. Difficult with such low trading volume to absorb the increased supply of shares without putting downward pressure on the share price.
- ·9.9. · MuokattuPharmaceutical company Vicore Pharma tops the list with a potential upside of 268%. The company develops treatments for lung diseases. Vicore has a drug candidate in a clinical study, with study data expected in 2027. In 2025, the company had a turnover of 3.8 Mkr and made a loss of 478 Mkr. Rank Company Upside to average target price in % 1 Vicore Pharma 268% 2 BioInvent International 267% 3 Verve Group Media 99% 4 Verisure 73% 5 Hansa Biopharma 69% Source: Factset
- ·4.9.Response from Vicore regarding ASPIRE and the path towards phase 3 I sent some questions to Vicore now that ASPIRE is fully recruited and the company is entering the waiting period for the results. Hans at Vicore replied: 1. Can a continued study after the futility analysis be seen as a positive sign? Response from Vicore: The futility analysis is conducted by an independent committee and Vicore will remain blinded to the results regarding treatment effect. A decision to continue the study only means that the committee has not identified reasons to discontinue the study due to a low probability of achieving the objective. 2. How much phase 3 work can be done already now? Response from Vicore: Some of the preparations can be made already before the ASPIRE results, for example CMC, clinical pharmacology, regulatory planning, market analyses, KOL dialogues and various scenarios for phase 3 design. The final decisions will, however, be based on ASPIRE data. 3. What will be most important when the ASPIRE results arrive? Response from Vicore: The primary endpoint, change in FVC over 52 weeks, will be central. At the same time, the overall picture will be important, including safety, tolerability and how the results position buloxibutid in the future treatment landscape for IPF. My own thought: I think the answers are quite clear. I would not interpret a decision to continue after the futility analysis as any confirmation of efficacy – Vicore themselves also state this clearly. However, I find it interesting that the company is already preparing several parts for a possible phase 3 study. They are thus working on the next step, while also being clear that the final decisions will be based on the ASPIRE results. Now, what truly remains is the most important thing: the FVC result after 52 weeks and the overall picture regarding efficacy, safety, and tolerability. That is where we will find out if buloxibutid truly has the potential to take the next big step. Thanks to the company for clear answers.
- ·2.9.In the coming days, several presentations of the company's product will be held at various conferences around the world. Funding to conduct the progressive operations in the form of studies, etc., is available. It will be interesting to see where the price settles in the future; today was a good opportunity to add to my position, which I have done. 🙏
- ·1.9.Danske Bank's increase of the target price to 25kr (20) might remind the market about the potential in this..
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 150 | - | - | ||
| 2 000 | - | - | ||
| 354 | - | - | ||
| 3 266 | - | - | ||
| 2 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 - tulosraportti 5.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 21.8. | ||
2026 Q1 - tulosraportti 6.5. | ||
2025 Q4 - tulosraportti 27.2. | ||
2025 Q3 - tulosraportti 5.11.2025 | ||
2025 Q2 - tulosraportti 22.8.2025 |
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 215 589 | 215 589 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 215 589 | 215 589 | 0 | 0 |
2026 Q2 - tulosraportti
Vain PDF
46 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 - tulosraportti 5.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 21.8. | ||
2026 Q1 - tulosraportti 6.5. | ||
2025 Q4 - tulosraportti 27.2. | ||
2025 Q3 - tulosraportti 5.11.2025 | ||
2025 Q2 - tulosraportti 22.8.2025 |
Tuotteita joiden kohde-etuutena tämä arvopaperi
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·11.9.The positive thing is that the decline so far does not seem to be linked to any new negative clinical announcement. The company's latest major announcement is still that ASPIRE is fully recruited and that topline data is expected in mid-2027.Short selling has increased steadily, at least 0.1% per day over the past 1-2 weeks. Difficult with such low trading volume to absorb the increased supply of shares without putting downward pressure on the share price.
- ·9.9. · MuokattuPharmaceutical company Vicore Pharma tops the list with a potential upside of 268%. The company develops treatments for lung diseases. Vicore has a drug candidate in a clinical study, with study data expected in 2027. In 2025, the company had a turnover of 3.8 Mkr and made a loss of 478 Mkr. Rank Company Upside to average target price in % 1 Vicore Pharma 268% 2 BioInvent International 267% 3 Verve Group Media 99% 4 Verisure 73% 5 Hansa Biopharma 69% Source: Factset
- ·4.9.Response from Vicore regarding ASPIRE and the path towards phase 3 I sent some questions to Vicore now that ASPIRE is fully recruited and the company is entering the waiting period for the results. Hans at Vicore replied: 1. Can a continued study after the futility analysis be seen as a positive sign? Response from Vicore: The futility analysis is conducted by an independent committee and Vicore will remain blinded to the results regarding treatment effect. A decision to continue the study only means that the committee has not identified reasons to discontinue the study due to a low probability of achieving the objective. 2. How much phase 3 work can be done already now? Response from Vicore: Some of the preparations can be made already before the ASPIRE results, for example CMC, clinical pharmacology, regulatory planning, market analyses, KOL dialogues and various scenarios for phase 3 design. The final decisions will, however, be based on ASPIRE data. 3. What will be most important when the ASPIRE results arrive? Response from Vicore: The primary endpoint, change in FVC over 52 weeks, will be central. At the same time, the overall picture will be important, including safety, tolerability and how the results position buloxibutid in the future treatment landscape for IPF. My own thought: I think the answers are quite clear. I would not interpret a decision to continue after the futility analysis as any confirmation of efficacy – Vicore themselves also state this clearly. However, I find it interesting that the company is already preparing several parts for a possible phase 3 study. They are thus working on the next step, while also being clear that the final decisions will be based on the ASPIRE results. Now, what truly remains is the most important thing: the FVC result after 52 weeks and the overall picture regarding efficacy, safety, and tolerability. That is where we will find out if buloxibutid truly has the potential to take the next big step. Thanks to the company for clear answers.
- ·2.9.In the coming days, several presentations of the company's product will be held at various conferences around the world. Funding to conduct the progressive operations in the form of studies, etc., is available. It will be interesting to see where the price settles in the future; today was a good opportunity to add to my position, which I have done. 🙏
- ·1.9.Danske Bank's increase of the target price to 25kr (20) might remind the market about the potential in this..
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 150 | - | - | ||
| 2 000 | - | - | ||
| 354 | - | - | ||
| 3 266 | - | - | ||
| 2 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 215 589 | 215 589 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 215 589 | 215 589 | 0 | 0 |